Strategic Analysis: The US Preclinical CRO Landscape 2026 The US market is undergoing a structural transformation as it moves away from traditional "fee-for-service" models toward strategic "R&D Partnerships." According to the latest US Preclinical CRO Market analysis, the industry is currently valued at approximately $2.8 billion in 2026. The primary growth driver is the explosion in Cell and Gene Therapy (CGT) pipelines, which require highly specialized preclinical expertise that small-to-mid-sized biotech firms cannot maintain in-house. https://www.marketresearchfuture.com/reports/us-preclinical-cro-market-49336 In 2026, the market is defined by the "AI-SDR" (AI-Supported Discovery Research) trend. CROs are no longer just execution arms; they are providing AI-driven predictive toxicology and lead optimization services. This has reduced the time from "Hit to Lead" by an average of 30%. Furthermore, the regional concentration in hubs like Boston, San Diego, and the Research Triangle Park (RTP) has led to a "Micro-CRO" ecosystem, where specialized boutique firms offer niche services in rare diseases and immunology. FAQ: Question: What is the main driver of the US market in 2026? Answer: The surge in Cell and Gene Therapy and the integration of AI-driven predictive analytics. Question: How much time does AI save in the preclinical phase? Answer: Current benchmarks show a 30% reduction in the timeline for lead optimization.